These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 15629358)

  • 41. Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells.
    Mossadegh N; Gissmann L; Müller M; Zentgraf H; Alonso A; Tomakidi P
    Virology; 2004 Aug; 326(1):57-66. PubMed ID: 15262495
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity.
    Liu W; Gao F; Zhao KN; Zhao W; Fernando GJ; Thomas R; Frazer IH
    Virology; 2002 Sep; 301(1):43-52. PubMed ID: 12359445
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity.
    Osen W; Peiler T; Ohlschläger P; Caldeira S; Faath S; Michel N; Müller M; Tommasino M; Jochmus I; Gissmann L
    Vaccine; 2001 Jul; 19(30):4276-86. PubMed ID: 11457555
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
    Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
    J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein.
    Di Bonito P; Grasso F; Mochi S; Petrone L; Fanales-Belasio E; Mei A; Cesolini A; Laconi G; Conrad H; Bernhard H; Dembek CJ; Cosma A; Santini SM; Lapenta C; Donati S; Muratori C; Giorgi C; Federico M
    Virology; 2009 Dec; 395(1):45-55. PubMed ID: 19800648
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein.
    Préville X; Ladant D; Timmerman B; Leclerc C
    Cancer Res; 2005 Jan; 65(2):641-9. PubMed ID: 15695409
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modified HPV16 E7/HSP70 DNA vaccine with high safety and enhanced cellular immunity represses murine lung metastatic tumors with downregulated expression of MHC class I molecules.
    Li H; Ou X; Xiong J
    Gynecol Oncol; 2007 Mar; 104(3):564-71. PubMed ID: 17081598
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-cancer activity of plant-produced HPV16 E7 vaccine.
    Massa S; Franconi R; Brandi R; Muller A; Mett V; Yusibov V; Venuti A
    Vaccine; 2007 Apr; 25(16):3018-21. PubMed ID: 17280752
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy.
    Bae SH; Park YJ; Park JB; Choi YS; Kim MS; Sin JI
    Clin Cancer Res; 2007 Jan; 13(1):341-9. PubMed ID: 17200373
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Maintenance of CD8 effector T cells by CD4 helper T cells eradicates growing tumors and promotes long-term tumor immunity.
    Lin CT; Chang TC; Shaw SW; Cheng PJ; Huang CT; Chao A; Soong YK; Lai CH
    Vaccine; 2006 Sep; 24(37-39):6199-207. PubMed ID: 16824651
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A single amino acid substitution improves the in vivo immunogenicity of the HPV16 oncoprotein E7(11-20) cytotoxic T lymphocyte epitope.
    Schreurs MW; Kueter EW; Scholten KB; Lemonnier FA; Meijer CJ; Hooijberg E
    Vaccine; 2005 Jul; 23(31):4005-10. PubMed ID: 15963358
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Construction of expression vector of hTERT- hIL18 fusion gene and induction of cytotoxic T lymphocyte response against hTERT.
    Tong XM; Zheng SE; Bader A; Yao HP; Wu NP; Altmeyer P; Brockmeyer NH; Jin J
    Eur J Med Res; 2008 Jan; 13(1):7-14. PubMed ID: 18226991
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel codon-optimized GM-CSF gene as an adjuvant to enhance the immunity of a DNA vaccine against HIV-1 Gag.
    Qiu JT; Chang TC; Lin CT; Chen YM; Li FQ; Soong YK; Lai CH
    Vaccine; 2007 Jan; 25(2):253-63. PubMed ID: 16971027
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria.
    Cortes-Perez NG; Lefèvre F; Corthier G; Adel-Patient K; Langella P; Bermúdez-Humarán LG
    Vaccine; 2007 Sep; 25(36):6581-8. PubMed ID: 17675182
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer.
    Lee DW; Anderson ME; Wu S; Lee JH
    Arch Otolaryngol Head Neck Surg; 2008 Dec; 134(12):1316-23. PubMed ID: 19075129
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multiple copies of a tumor epitope in a recombinant hepatitis B surface antigen (HBsAg) vaccine enhance CTL responses, but not tumor protection.
    Haigh O; Guo H; Edgtton K; Mather M; Herd KA; Tindle RW
    Virology; 2007 Nov; 368(2):363-75. PubMed ID: 17689584
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies.
    Bolhassani A; Zahedifard F; Taghikhani M; Rafati S
    Vaccine; 2008 Jun; 26(26):3362-70. PubMed ID: 18471945
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Endoplasmic reticulum targeting sequence enhances HBV-specific cytotoxic T lymphocytes induced by a CTL epitope-based DNA vaccine.
    Xu W; Chu Y; Zhang R; Xu H; Wang Y; Xiong S
    Virology; 2005 Apr; 334(2):255-63. PubMed ID: 15780875
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antigen-specific CD8+ T lymphocytes generated from a DNA vaccine control tumors through the Fas-FasL pathway.
    Cheng WF; Lee CN; Chang MC; Su YN; Chen CA; Hsieh CY
    Mol Ther; 2005 Nov; 12(5):960-8. PubMed ID: 15979942
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers.
    Xu M; Lu X; Sposato M; Zinckgraf JW; Wu S; von Hofe E
    Vaccine; 2009 Jul; 27(34):4641-7. PubMed ID: 19520206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.